{"entity":{"id":"nct06109779","kind":"trial","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","aka":["ARTEMIDE-Biliary01"],"tldr":"A phase 3 trial of Rilvegostomig, Capecitabine and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) is a phase 3 interventional study registered as NCT06109779 by AstraZeneca, with 760 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2029-01-02. Interventions recorded: Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin and S-1 [Tegafur/Oteracil/gimeracil].","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06109779","url":"https://clinicaltrials.gov/study/NCT06109779"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["rilvegostomig","capecitabine","gemcitabine-cisplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06109779","phase":"3","setting":"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)","sponsor":"AstraZeneca","started":"2023-12-04","startedType":"actual","enrolled":760,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06109779/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"roadmap":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"}],"idea":[{"id":"idea-gbc-report-gallbladder-separately-in-biliary-trials","kind":"idea","name":"Report gallbladder cancer as its own population in every biliary trial","route":"/ideas/idea-gbc-report-gallbladder-separately-in-biliary-trials/"}]}}